Teva Pharmaceutical Industries announced today that the US Food and Drug Administration granted tentative approval for the company's ANDA for Carboplatin Injection, 50 milligrams, 150 milligrams, and 450 milligrams.
Carboplatin Injection is the generic equivalent of Bristol-Myers Squibb's Paraplatin. The product is indicated for the treatment of cancer. The brand product has annual sales of approximately $ 513 million.
Teva Pharmaceutical Industries, headquartered in Israel, is among the top 35 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 80 percent of Teva's sales are in North America and Europe. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. — (menareport.com)
© 2003 Mena Report (www.menareport.com)
